Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy.
Dendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). D...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0264674 |
| _version_ | 1797771601870061568 |
|---|---|
| author | Sara Anvari Levi B Watkin Charles G Minard Kimberly Schuster Oluwatomi Hassan Aikaterini Anagnostou Jordan S Orange David B Corry Carla M Davis |
| author_facet | Sara Anvari Levi B Watkin Charles G Minard Kimberly Schuster Oluwatomi Hassan Aikaterini Anagnostou Jordan S Orange David B Corry Carla M Davis |
| author_sort | Sara Anvari |
| collection | DOAJ |
| description | Dendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). Delineation of early immunologic changes contributing to desensitization would help clarify the POIT mechanism of action. We analyzed dendritic cells in 15 pediatric subjects (5-12 years) undergoing a phase 1 single-center POIT study. We examined dendritic cells at baseline, 6-, 12-, 18- and 24-weeks after initiation of POIT and responders of therapy were compared to non-responders and healthy controls. The distribution frequency of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) from peripheral blood samples were measured in vitro. A general linear mixed model was used, and included fixed effects for cohort (responder, non-responder, or healthy control), time (0-, 6-, 12-, 18-, and 24-weeks), and the cohort-time interaction term. P-values were adjusted for multiple hypothesis testing using Tukey's method. We observed that POIT responders had reduced TNFa producing myeloid dendritic cells (mDCs) compared to non-responders. Additionally, non-responders had increased OX40L expressing mDCs at 18-weeks compared to responders. In conclusion, our findings suggest that a reduced pro-inflammatory phenotype in DCs could potentially serve as a predictor of early outcome and success of POIT desensitization. |
| first_indexed | 2024-03-12T21:39:59Z |
| format | Article |
| id | doaj.art-f72371d7158a42e3ae27743a67665d16 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-12T21:39:59Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f72371d7158a42e3ae27743a67665d162023-07-27T05:31:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01175e026467410.1371/journal.pone.0264674Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy.Sara AnvariLevi B WatkinCharles G MinardKimberly SchusterOluwatomi HassanAikaterini AnagnostouJordan S OrangeDavid B CorryCarla M DavisDendritic cells are important mediators in the early presentation of antigen and regulation of the differentiation of T cells. Peanut oral immunotherapy (POIT) results in desensitization in most peanut allergic individuals (responders), but not in others due to allergic reactions (non-responders). Delineation of early immunologic changes contributing to desensitization would help clarify the POIT mechanism of action. We analyzed dendritic cells in 15 pediatric subjects (5-12 years) undergoing a phase 1 single-center POIT study. We examined dendritic cells at baseline, 6-, 12-, 18- and 24-weeks after initiation of POIT and responders of therapy were compared to non-responders and healthy controls. The distribution frequency of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) from peripheral blood samples were measured in vitro. A general linear mixed model was used, and included fixed effects for cohort (responder, non-responder, or healthy control), time (0-, 6-, 12-, 18-, and 24-weeks), and the cohort-time interaction term. P-values were adjusted for multiple hypothesis testing using Tukey's method. We observed that POIT responders had reduced TNFa producing myeloid dendritic cells (mDCs) compared to non-responders. Additionally, non-responders had increased OX40L expressing mDCs at 18-weeks compared to responders. In conclusion, our findings suggest that a reduced pro-inflammatory phenotype in DCs could potentially serve as a predictor of early outcome and success of POIT desensitization.https://doi.org/10.1371/journal.pone.0264674 |
| spellingShingle | Sara Anvari Levi B Watkin Charles G Minard Kimberly Schuster Oluwatomi Hassan Aikaterini Anagnostou Jordan S Orange David B Corry Carla M Davis Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. PLoS ONE |
| title | Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. |
| title_full | Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. |
| title_fullStr | Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. |
| title_full_unstemmed | Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. |
| title_short | Reduced pro-inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy. |
| title_sort | reduced pro inflammatory dendritic cell phenotypes are a potential indicator of successful peanut oral immunotherapy |
| url | https://doi.org/10.1371/journal.pone.0264674 |
| work_keys_str_mv | AT saraanvari reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT levibwatkin reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT charlesgminard reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT kimberlyschuster reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT oluwatomihassan reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT aikaterinianagnostou reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT jordansorange reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT davidbcorry reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy AT carlamdavis reducedproinflammatorydendriticcellphenotypesareapotentialindicatorofsuccessfulpeanutoralimmunotherapy |